bf/NASDAQ:PTGX_icon.png

NASDAQ:PTGX

Protagonist Therapeutics Inc.

  • Stock

44.99

−1.81%

−11.73

USD last updated 14/08 01:46:41

Last Close

56.72

13/08 20:01

Market Cap

2.04B

Beta: 1.95

Volume Today

739.46K

Avg: 1.73M

PE Ratio

−11.44

PFCF: −12.63

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -11232018-11-062020-05-072022-02-282023-08-032024-11-07

    Revenue (Estimate*)

    50M100M150M200M250M2018-11-062020-05-072022-02-282023-08-032024-11-07

    *Estimate based on analyst consensus